Clinical trial

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in…

NCT04292730 · Gilead Sciences, Industry · Completed

Key facts

NCT number NCT04292730
Title Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
Official title A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
Lead sponsor Gilead Sciences, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions COVID-19
Intervention type Drug
Interventions Remdesivir, Standard of Care
Enrollment 1,113
Start date Mar 15, 2020
Primary completion Apr 29, 2020
Completion Jun 26, 2020
First posted Mar 3, 2020
Last update posted Jan 26, 2021
Countries China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland and 3 more

At a glance

  • 100–999 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies